Belharra Therapeutics Debuts With $130 Million in Funding – Belharra Therapeutics
Summary
Parker and Cravatt developed a novel photoaffinity-based chemoproteomics technology to enable screening for small molecules that bind proteins in their native context and focused it on immunology targets leveraging the expertise of Dr. Teijaro. During Dr. Teijaros graduate and post-graduate training, his research specialized in molecular and temporal immunologic features linked to viral infection and autoimmunity, publishing many papers on costimulation and cytokine activation in the laboratories of Donna Farber and Michael Oldstone, respectively. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Guided by a diverse team of biotech trailblazers, Belharras proprietary discovery engine is uniquely capable of identifying novel, non-covalent small molecule starting points for developing transformative medicines to address previously difficult-to-treat diseases and conditions. The companys next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type.